Lupin Limited (LUPIN) — Financial Results | 5 August 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Lupin Limited reported Q1 FY2026 net profit of ₹12,215 crores, up 51.6% YoY, driven by sales growth of 11.8% to ₹61,638 crores. EBITDA surged 38% to ₹18,063 crores with margin expansion of 560 basis points to 29.3%. U.S. operations grew 24.3%, while India sales increased 7.8%. The company maintains its position as the 3rd largest generic player in the U.S. market with 139 marketed products. API sales declined 32.9% sequentially.

📄 View Original Announcement (PDF)

About Lupin Limited (LUPIN)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,04,071.47 Cr P/E: 36.2

View full LUPIN stock details →

📡 Get AI alerts when LUPIN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LUPIN — Free

📊 More LUPIN filings

See all LUPIN filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LUPIN files new disclosures

Track LUPIN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LUPIN — Free

Free account · 2 AI queries/day